Expert opinion on drug delivery最新文献

Introduction: Vocal fold (VF) scarring poses a significant challenge. It is characterized by prolonged and often irreversible impairment of vocal function due to loss of pliability and disruption of the lamina propria's native extracellular matrix. Current treatments remain largely palliative, aiming to improve glottic closure rather than restore normal tissue biomechanics. As research deepens into the wound healing pathways and fibrotic mechanisms underlying scar formation, injectable therapies are emerging as approaches to modulate healing and restore vibratory function.

Areas covered: This review outlines the pathophysiology of VF scarring and evaluates emerging injectable strategies designed to restore tissue architecture and function. These include biomaterial-based implants, antifibrotic and pro-regenerative biologics, stem cell therapies, and advanced drug delivery systems. The translational challenges include anatomical constraints, delivery precision, animal models, immune compatibility, degradation kinetics, and the lack of standardized outcome measures.

Expert opinion: The review highlights the ongoing research on injections of implants for VF scarring that support biomechanical properties and modulate local tissue repair. However, further advanced and long-term studies, including clinical trials, are needed to fully elucidate their safety, efficacy, and toxicity profiles. In addition, their scalability and reproducibility within pharmaceutical manufacturing must be rigorously validated to support clinical translation.

Introduction: Recent advances in nanoformulations are reshaping the treatment landscape for helminthiasis by addressing critical challenges such as drug resistance, poor bioavailability, and off-target effects.

Areas covered: This review examines current innovations in nanotechnology applied to anthelmintic therapy, with a particular focus on lipid- and polymer-based systems designed to enhance drug solubility, stability, and targeted delivery. A comprehensive literature search was performed to identify recent developments, highlight preclinical and translational studies, and evaluate the performance of solid lipid nanoparticles, nanoemulsions, and self-nanoemulsifying drug delivery systems. Relevant articles were retrieved from peer-reviewed journals indexed in PubMed, Scopus, and Web of Science, covering publications up to June 2025.

Expert opinion: The integration of nanotechnologies into helminthiasis treatment offers promising therapeutic advantages but faces important challenges related to industrial scalability, regulatory approval, and implementation in low-resource settings. Addressing these issues requires coordinated efforts between academia, industry, and public health stakeholders. The review outlines key considerations for technology transfer and commercialization, underscoring the importance of cost-effectiveness, patient acceptability, and cross-sector collaboration to ensure the successful translation of nanomedicine-based solutions for neglected tropical diseases.

Introduction: Cystic fibrosis (CF) is a genetic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, leading to impaired ion transport by the CFTR protein and accumulation of thick, sticky mucus, resulting in chronic lung disease and other organ complications. Messenger ribonucleic acid (mRNA) therapies hold great potential for CF, as they can be used for both CFTR mRNA replacement and editing of the CFTR gene, which could mitigate the pathophysiological and clinical symptoms of CF.

Areas covered: We provide an overview of non-viral mRNA therapies for CF and their ongoing clinical trials. We begin with a discussion of the pathophysiological functions of CFTR and clinical symptoms of CF. We provide a summary of conventional treatments, modulator therapies, and potential gene therapies for CF. We discuss the pertinence of mRNA therapies for CF as well as the challenges associated with mRNA delivery. We conclude with an overview of non-viral vectors for mRNA delivery and a summary of clinical trials for CFTR mRNA therapies. Literature searches for this review were performed using databases (Google Scholar and PubMed).

Expert opinion: With continued innovation and overcoming of delivery challenges, mRNA therapies hold great potential for the treatment of people with CF, regardless of mutation.

Introduction: Pediatric intranasal (IN) drug delivery is a promising noninvasive way of administering medication, offering a significant improvement over parenteral and oral methods. However, its effectiveness is hindered by major technical challenges, primarily stemming from the wide anatomical variations among children and the difficulty in achieving consistent dosing. This expert opinion explores an integrated approach to overcome these obstacles.

Areas covered: This article summarizes the recent literature on technological strategies used to address challenges in pediatric drug delivery, focusing on studies published between January 2015 to December 2025, sourced from Google Scholar and PubMed. It discusses how advancements in formulation and device engineering are improving drug deposition and absorption. The article also highlights the relevance of regional deposition to two emerging applications: nose-to-brain drug delivery and intranasal vaccines, while also covering the challenges of the nasal mucus barrier and novel formulation strategies to overcome it.

Expert opinion: The future of pediatric IN delivery lies in the coordinated advancement of multiple interdependent factors. By treating a child's unique anatomy and physiology as key design parameters, researchers can integrate physical and computational models to simultaneously optimize formulations, devices, and delivery techniques. This multifactorial strategy will lead to highly reliable and personalized therapies.

Introduction: Peptides play diverse roles in biological processes, including drug discovery, antibacterial activity, and protein-protein interactions, making peptide prediction a crucial field. The development of bioinformatics tools has significantly enhanced our ability to study and harness peptide potential. Among these, cell-penetrating peptides (CPP) are a unique class of polypeptides capable of crossing cell membranes, facilitating the intracellular delivery of therapeutic agents such as small molecules, peptides, proteins, and nucleic acids. This ability has expanded possibilities in drug delivery, gene therapy, and molecular imaging. However, identifying and designing effective CPP remains challenging.

Areas covered: In recent years, various computational tools and algorithms have been developed to predict the cell-penetration potential of peptides, aiding in the discovery of novel CPP and accelerating their applications. This review provides a comprehensive overview of bioinformatics tools including artificial intelligence (AI) for peptide prediction, with a particular focus on CPP. Systematic literature search was performed from PubMed, Embase, Scopus, and the Web of Science to cover published references related to the current topic from 2011 to October 2025.

Expert opinion: Understanding their functions and limitations will help researchers make informed decisions and effectively utilize peptide prediction in diverse scientific and clinical applications.

Introduction: Conventional drug delivery for cancer therapy often suffer from poor targeting efficiency, limited bioavailability, and severe off-target toxicity. Nanoparticle-based approaches have emerged as transformative alternatives, particularly when integrated with microfluidic technologies. In the context of liver cancer, microfluidic-assisted polymeric nanocarriers provide a highly controllable and reproducible route for improving drug delivery outcomes.

Areas covered: We cover recent developments in polymeric nanoparticle systems; their integration with microfluidic fabrication platforms for liver cancer therapy; the ability to encapsulate therapeutic agents, achieve controlled release, and facilitate passive and active tumor targeting through physicochemical modulation and ligand functionalization; microfluidic-assisted synthesis, which enables fine-tuned control over particle size, surface chemistry, and payload distribution with minimal batch-to-batch variation; PEGylated PLGA, cyclodextrin-based, and stimuli-responsive polymeric nanocarriers, highlighting their potential in overcoming biological barriers and enhancing therapeutic index.

Expert opinion: Microfluidic-assisted nanoparticle fabrication represents a paradigm shift in the design and clinical translation of targeted therapies for liver cancer. By allowing real-time control over nanoparticle synthesis and enabling combination delivery strategies, this approach holds great promise for personalized and precision oncology. Continued integration of microfluidic engineering with biomaterial science and clinical insights is expected to accelerate the realization of safe, reproducible, and patient-tailored nanotherapeutics for hepatocellular carcinoma.

Introduction: Conventional drug delivery systems in cancer therapy face limitations such as poor targeting and adverse side effects. Nanoparticle-based approaches, particularly when integrated with microfluidic technology, have emerged as promising strategies to improve therapeutic precision and outcomes, especially in liver cancer treatment.

Areas covered: This review discusses recent progress in the use of nanoparticles and polymers for targeted drug delivery, highlighting their ability to encapsulate therapeutic agents and release them at specific sites. The role of microfluidic platforms in drug loading is emphasized, as they enable precise manipulation at micro- and nanoscale levels with minimal sample loss. Literature examining the use of polymer-based nanocarriers, microfluidic-assisted drug encapsulation, and their applications in overcoming tumor growth and liver cancer therapy is analyzed. The article also explores the advantages of microfluidics as a tool for fabricating complex nanosystems for controlled and efficient delivery.

Expert opinion: Microfluidic-assisted nanoparticle delivery represents a highly promising approach for advancing liver cancer treatment. With its potential to support combination therapies and enable intricate, customizable nanosystems, this platform is likely to shape the future of targeted cancer therapeutics.